Save Article

Bristol-Myers Extends Abilify Sales Pact

Bristol-Myers Squibb Co. is extending its U.S. marketing partnership with Japan's Otsuka Pharmaceutical Co. on the blockbuster psychiatric drug Abilify, potentially bringing Bristol-Myers billions of dollars more in revenue.

Like others in the industry, Bristol-Myers faces the prospect of substantial revenue losses from patent expirations, and the extension eliminates the potential loss of another key revenue stream. Its marketing rights to Abilify, the New York company's second-biggest seller, with $2 billion in 2008 revenue,...